MBX Biosciences
在场
MBX Biosciences 是一家在股票代码 MBX (US) 下上市的公司。
高管
查看带有其 16 名主要高管的组织结构图
MBX Biosciences 搜索最多的简介
高管在MBX Biosciences变化
- Steven Ryder已作为Director加入公司 (新闻发布的2024二月6号).
- Michelle Graham已作为Chief Human Resources Officer加入公司 (新闻发布的2023十一月1号).
创建提醒
跟踪 MBX Biosciences 的高管变动
生物技术
MBX Biosciences 拥有 2,281 家竞争者，其中包括 Lonza (瑞士)、Eurofins (卢森堡) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Endeavor BioMedicines 刚刚宣布为 132 筹款数百万美元。 (公布2024四月25号).
- Metsera 刚刚宣布为 290 筹款数百万美元。 (公布2024四月23号).
- Histogen has filed for bankruptcy protection (公布2024四月19号).
生物技术 行业的其他推荐联系人
消息
MBX Biosciences 的最新新闻稿
- MBX Biosciences to Participate in Piper Sandler 35th Annual Healthcare Conference | MBX Biosciences
- MBX Biosciences to Participate in Stifel 2023 Healthcare Conference | MBX Biosciences
- MBX Biosciences Announces Appointment of Michelle Graham as Chief Human Resources Officer | MBX Biosciences
- MBX Biosciences Presents Positive Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research Annual Meeting | MBX Biosciences
- MBX Biosciences Doses First Participant in Phase 1/2 Clinical Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia | MBX Biosciences
- MBX Biosciences to Showcase Results from Phase 1 Study of MBX 2109 in Late-Breaking Oral Presentation at the American Society for Bone and Mineral Research Annual Meeting | MBX Biosciences
- MBX Biosciences Announces Positive Phase 1 Multiple Ascending Dose Data for MBX 2109, a Long-Acting Parathyroid Hormone Peptide Prodrug, in Healthy Adults | MBX Biosciences
- MBX Biosciences Announces U.S. FDA Clearance of IND Application for MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia | MBX Biosciences
- MBX Biosciences Appoints Steven J. Prestrelski, Ph.D., M.B.A., as Chief Scientific Officer | MBX Biosciences
- MBX Biosciences to Participate in Jefferies Healthcare Conference | MBX Biosciences
- View more press releases Close
通过电子邮件
